These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 38857662)
41. Continuous in-line homogenization process for scale-up production of naltrexone-loaded PLGA microparticles. Sharifi F; Otte A; Yoon G; Park K J Control Release; 2020 Sep; 325():347-358. PubMed ID: 32645336 [TBL] [Abstract][Full Text] [Related]
42. Prediction of dexamethasone release from PLGA microspheres prepared with polymer blends using a design of experiment approach. Gu B; Burgess DJ Int J Pharm; 2015 Nov; 495(1):393-403. PubMed ID: 26325309 [TBL] [Abstract][Full Text] [Related]
43. Design of physostigmine-loaded polymeric microparticles for pretreatment against exposure to organophosphate agents. Chaw CS; Tan CW; Yang YY; Wang L; Moochhala S Biomaterials; 2003 Mar; 24(7):1271-7. PubMed ID: 12527268 [TBL] [Abstract][Full Text] [Related]
46. Preparation and in vitro/in vivo evaluation of insulin-loaded poly(acryloyl-hydroxyethyl starch)-PLGA composite microspheres. Jiang G; Qiu W; DeLuca PP Pharm Res; 2003 Mar; 20(3):452-9. PubMed ID: 12669968 [TBL] [Abstract][Full Text] [Related]
47. PLGA-based microparticles loaded with bacterial-synthesized prodigiosin for anticancer drug release: Effects of particle size on drug release kinetics and cell viability. Obayemi JD; Danyuo Y; Dozie-Nwachukwu S; Odusanya OS; Anuku N; Malatesta K; Yu W; Uhrich KE; Soboyejo WO Mater Sci Eng C Mater Biol Appl; 2016 Sep; 66():51-65. PubMed ID: 27207038 [TBL] [Abstract][Full Text] [Related]
48. Improved bioavailability of orally delivered insulin using Eudragit-L30D coated PLGA microparticles. Naha PC; Kanchan V; Manna PK; Panda AK J Microencapsul; 2008 Jun; 25(4):248-56. PubMed ID: 18465311 [TBL] [Abstract][Full Text] [Related]
49. Antioxidant encapsulated porous poly(lactide-co-glycolide) microparticles for developing long acting inhalation system. Yoo NY; Youn YS; Oh NM; Oh KT; Lee DK; Cha KH; Oh YT; Lee ES Colloids Surf B Biointerfaces; 2011 Nov; 88(1):419-24. PubMed ID: 21820282 [TBL] [Abstract][Full Text] [Related]
50. How porosity and size affect the drug release mechanisms from PLGA-based microparticles. Klose D; Siepmann F; Elkharraz K; Krenzlin S; Siepmann J Int J Pharm; 2006 May; 314(2):198-206. PubMed ID: 16504431 [TBL] [Abstract][Full Text] [Related]
51. The effect of different grades of PLGA on characteristics of microspheres encapsulated with cyclosporine A. Malaekeh-Nikouei B; Sajadi Tabassi SA; Jaafari MR Curr Drug Deliv; 2006 Oct; 3(4):343-9. PubMed ID: 17076635 [TBL] [Abstract][Full Text] [Related]
52. Combinatorial co-encapsulation of hydrophobic molecules in poly(lactide-co-glycolide) microparticles. Acharya AP; Lewis JS; Keselowsky BG Biomaterials; 2013 Apr; 34(13):3422-30. PubMed ID: 23375950 [TBL] [Abstract][Full Text] [Related]
53. Subconjunctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model. Ayalasomayajula SP; Kompella UB Eur J Pharmacol; 2005 Mar; 511(2-3):191-8. PubMed ID: 15792788 [TBL] [Abstract][Full Text] [Related]
54. Mechanistic explanation of the (up to) 3 release phases of PLGA microparticles: Monolithic dispersions studied at lower temperatures. Tamani F; Bassand C; Hamoudi MC; Siepmann F; Siepmann J Int J Pharm; 2021 Mar; 596():120220. PubMed ID: 33486018 [TBL] [Abstract][Full Text] [Related]
55. A biodegradable polymeric system for peptide-protein delivery assembled with porous microspheres and nanoparticles, using an adsorption/infiltration process. Alcalá-Alcalá S; Urbán-Morlán Z; Aguilar-Rosas I; Quintanar-Guerrero D Int J Nanomedicine; 2013; 8():2141-51. PubMed ID: 23788833 [TBL] [Abstract][Full Text] [Related]
56. Initial Formation of the Skin Layer of PLGA Microparticles. Sharifi F; Otte A; Park K Adv Healthc Mater; 2022 Apr; 11(7):e2101427. PubMed ID: 34601826 [TBL] [Abstract][Full Text] [Related]
57. Design of Highly Dispersible PLGA Microparticles in Aqueous Fluid for the Development of Long-Acting Release Injectables. Nakashima A; Izumi T; Ohya K; Kondo K; Niwa T Chem Pharm Bull (Tokyo); 2017; 65(2):157-165. PubMed ID: 28154309 [TBL] [Abstract][Full Text] [Related]
58. Preparation, characterization, and in vitro and in vivo investigation of chitosan-coated poly (d,l-lactide-co-glycolide) nanoparticles for intestinal delivery of exendin-4. Wang M; Zhang Y; Feng J; Gu T; Dong Q; Yang X; Sun Y; Wu Y; Chen Y; Kong W Int J Nanomedicine; 2013; 8():1141-54. PubMed ID: 23658482 [TBL] [Abstract][Full Text] [Related]
59. Influence of formulation parameters on the characteristics of poly(D, L-lactide-co-glycolide) microspheres containing poly(L-lysine) complexed plasmid DNA. Capan Y; Woo BH; Gebrekidan S; Ahmed S; DeLuca PP J Control Release; 1999 Aug; 60(2-3):279-86. PubMed ID: 10425333 [TBL] [Abstract][Full Text] [Related]
60. Development and In Vivo Evaluation of Sustained Release Microparticles Loaded with Levothyroxine for Hypothyroidism Treatment. Alhawari HH; Abuhamdan RM; Alrashdan M; Al Thaher Y; Shraideh ZA; Abulateefeh SR J Pharm Sci; 2024 Jun; 113(6):1566-1571. PubMed ID: 38232803 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]